GlassScriptPhysician profile
Jordan Killis Gould
NPI 1972041028
$7,444.20
in general payments reported to CMS, 2019-2025
48 companies · $1,734 in 2025
The $1,734 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.92 · 2020: $35.53 · 2021: $128 · 2022: $413 · 2023: $1,774 · 2024: $3,272 · 2025: $1,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,602 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,602.29 |
| Education | $178.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,478.92 | 2022-2025 | |
| Ucb, INC. | $733.16 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $389.61 | 2022-2025 | Austedo Xr, Austedo, Ajovy |
| Novartis Pharmaceuticals Corporation | $378.31 | 2023-2025 | |
| Celgene Corporation | $351.69 | 2023-2025 | Zeposia |
| Livanova USA, INC. | $323.19 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Sk Life Science, INC. | $310.64 | 2022-2024 | Xcopri |
| Pfizer INC. | $292.10 | 2023-2025 | |
| Neurelis, INC. | $262.31 | 2023-2024 | Valtoco |
| Lundbeck LLC | $250.07 | 2023-2025 | Vyepti, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $209.36 | 2023-2025 | Hyqvia |
| Neurocrine Biosciences, INC. | $196.37 | 2023-2025 | Ingrezza, Ongentys |
| Grifols USA, LLC | $194.12 | 2024-2025 | Gamunex-C |
| Jazz Pharmaceuticals INC. | $176.99 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $162.64 | 2023-2025 | Nuplazid, Daybue |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Imperative Care, INC | $156.14 | 2022-2025 | Zoom 88-T Large Distal Platform |
| Argenx US, INC. | $144.75 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Janssen Pharmaceuticals, INC | $124.99 | 2023 | Xarelto |
| Octapharma USA, INC. | $120.00 | 2023-2024 | Panzyga |
| Neuropace, INC. | $94.39 | 2024-2025 | |
| Mdd US Operations, LLC | $86.92 | 2019 | |
| Immedica Pharma US, INC. | $78.79 | 2022-2024 | |
| Lilly USA, LLC | $77.94 | 2020-2024 | Amyvid, Kisunla, Emgality |
| Catalyst Pharmaceuticals, INC. | $77.81 | 2023-2024 | Fycompa |
| Otter Pharmaceuticals, LLC | $74.91 | 2024 | Sympazan |
| Emd Serono, INC. | $67.54 | 2023-2024 | Mavenclad |
| Sumitomo Pharma America, INC. | $65.07 | 2023-2024 | Aptiom |
| Biogen, INC. | $60.48 | 2024-2025 | Leqembi |
| Averitas Pharma INC. | $50.26 | 2024 | Qutenza |
| Eisai INC. | $43.74 | 2025 | |
| Medtronic, INC. | $38.17 | 2024-2025 | Percept PC Brainsense |
| Ge Healthcare | $35.51 | 2024 | |
| Genentech USA, INC. | $30.04 | 2024-2025 | Enspryng, Ocrevus, Ocrevus Zunovo |
| Ani Pharmaceuticals, INC. | $28.17 | 2025 | Purified Cortrophin Gel |
| Acorda Therapeutics, INC | $26.58 | 2023 | Inbrija |
| Astrazeneca Pharmaceuticals LP | $24.94 | 2024 | Andexxa |
| Alnylam Pharmaceuticals INC. | $23.57 | 2024 | Onpattro |
| Bolton Medical INC | $22.53 | 2024 | Glidesheath Slender |
| Boston Scientific Corporation | $20.67 | 2024 | |
| Harmony Biosciences LLC | $20.46 | 2025 | |
| Vanda Pharmaceuticals INC. | $19.60 | 2024 | Ponvory |
| Azurity Pharmaceuticals, INC. | $19.23 | 2024 | Horizant |
| Upsher-Smith Laboratories LLC | $18.83 | 2020 | |
| Aucta Pharmaceuticals, INC. | $17.76 | 2025 | Motpoly Xr |
| Axsome Therapeutics, INC. | $17.63 | 2024 | Sunosi |
| Csl Behring | $16.70 | 2025 | Hizentra |
| Merz Pharmaceuticals, LLC | $15.82 | 2024 | Inbrija |
| Amgen INC. | $14.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Gould listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.